Our Pipeline
Reimagines Antibody-Drug Conjugates
Early pipeline is focused on developing dual-payload conjugates (drug-to-antibody ratio [DAR] 2+4) in tumors with high unmet need. Our lead asset targeting TROP2 demonstrates significant superiority to leading antibody-drug conjugates (ADCs) in hard-to-treat in vivo models while being well tolerated with no observed toxicity.
Abbreviations: GPC3, glypican 3; HER2, human epidermal growth factor receptor 2; IND, investigational new drug application; POC, proof of concept; TROP2, trophoblast cell surface antigen 2.